较高的腹腔内脏脂肪质量与炎症性肠病患者启动生物制剂治疗后临床及内镜缓解率较低相关:Constellation研究结果
前瞻性纳入141例活动性炎症性肠病患者(启动英夫利西单抗、维得利珠单抗或乌司奴单抗)及51例健康对照,用GE iDXA测量基线体成分。腹腔内脏脂肪占总体质量百分比较高(IA-VAT%较高)的患者,无激素深度缓解(P<.001)和内镜缓解(P=.02)的可能性较低。IA-VAT%较高是无激素深度缓解较差的独立相关因素,该关联可能部分由炎症细胞因子表达的差异驱动。
要点
- IA-VAT%较高的IBD患者达到无激素深度缓解(P<.001)和内镜缓解(P=.02)的可能性较低。
- 高IA-VAT%组中无应答者的基线血清白细胞介素-6和肿瘤坏死因子显著高于应答者及低IA-VAT%患者。
- 高与低IA-VAT%组的药物药代动力学特征及微生物群多样性相似。
核心结论
- 较高的IA-VAT%独立地与较差结局相关,该关联可能至少部分由炎症细胞因子表达的差异驱动。
研究设计与样本
- 前瞻性纳入活动性IBD并启动英夫利西单抗、维得利珠单抗或乌司奴单抗的患者及健康对照组。
- 共纳入141例IBD患者和51例健康对照,基线体成分(含IA-VAT占总体质量百分比IA-VAT%)用GE iDXA扫描测量。
- 主要结局为第14-16周无激素深度缓解(克罗恩病Harvey Bradshaw指数<5、溃疡性结肠炎部分Mayo评分<2,且C反应蛋白和粪钙卫蛋白正常)。
- 次要结局为第30-46周无激素深度缓解和内镜缓解(溃疡性结肠炎内镜Mayo评分≤1或克罗恩病简化内镜评分≤2)。
主要发现
- IBD组与健康对照组之间体成分参数未见差异。
- IA-VAT%较高的患者较IA-VAT%较低者更少达到无激素深度缓解(P<.001)。
- IA-VAT%较高的患者较IA-VAT%较低者更少达到内镜缓解(P=.02)。
- 高IA-VAT%组中无应答者的基线血清白细胞介素-6和肿瘤坏死因子显著高于应答者及低IA-VAT%患者。
- 高与低IA-VAT%组的药物药代动力学特征和微生物群多样性相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We sought to assess the association between intra-abdominal visceral adipose tissue (IA-VAT) and response to 3 different biologic drugs in patients with inflammatory bowel disease (IBD) and to investigate its effects on inflammatory cytokine expression, pharmacokinetics, and intestinal microbiota. METHODS: We prospectively enrolled subjects with active IBD initiating infliximab, vedolizumab, or ustekinumab and a healthy control group. Baseline body composition (including IA-VAT as percent of total body mass [IA-VAT%]) was measured using GE iDXA scan. Primary outcome was corticosteroid- free deep remission at weeks 14-16, defined as Harvey Bradshaw Index <5 for Crohn's disease and partial Mayo score <2 for ulcerative colitis, with a normal C-reactive protein and fecal calprotectin. Secondary outcomes were corticosteroid-free deep remission and endoscopic remission (Endoscopic Mayo Score ≤1 in ulcerative colitis or Simple Endoscopic Score for Crohn's disease ≤2) at weeks 30-46. RESULTS: A total of 141 patients with IBD and 51 healthy controls were included. No differences in body composition parameters were seen between the IBD and healthy control cohorts. Patients with higher IA-VAT% were less likely to achieve corticosteroid-free deep remission (P < .001) or endoscopic remission (P = .02) vs those with lower IA-VAT%. Furthermore, nonresponders with high IA-VAT% had significantly higher serum interleukin-6 and tumor necrosis factor at baseline compared with responders and patients with low IA-VAT%. Drug pharmacokinetic properties and microbiota diversity were similar when comparing high and low IA-VAT% groups. CONCLUSIONS: Higher IA-VAT% was independently associated with worse outcomes. This association could be driven at least partially by discrete differences in inflammatory cytokine expression.
引用
- Yarur AJ, Bruss A, Moosreiner A, et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023. PMID: 37499955. doi:10.1053/j.gastro.2023.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。